ArticleNature2022
Phage anti-CBASS and anti-Pycsar nucleases subvert bacterial immunity.
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 179 citations in OpenAlex.
- Molecular control of bacterial immunity.Nature structural & molecular biology · 2026Review
- Structural basis of assembly-dependent activation of the MAD3-MAD4 nuclease in the Pseudomonas aeruginosa MADS defense system.Nucleic acids research · 2026Article
- Training a phage to expand its host range: directed evolution againstAntimicrobial agents and chemotherapy · 2026Article
- How bacterial immune systems sense phage infection.Nature reviews. Microbiology · 2026Review
- Revisiting the life cycle of temperate phages.Nature reviews. Microbiology · 2026Review
- Characterization of defensome genes and mobile genetic Elements in different types of pasture soil agroecosystems from the Brazilian Amazon.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Systematic mapping of bacteriophage gene essentiality with HIDEN-SEQ.Nature microbiology · 2026Article
- Bacteriophage-bacteria coevolution: from molecular arms races to ecological and applied perspectives.Archives of microbiology · 2026Review
- Cyclic tri-adenylate controls a CARF-TM effector in type II Panoptes anti-phage systems.PLoS biology · 2026Article
- Convergent evolution of viral nucleases targeting cyclic dinucleotides.PLoS pathogens · 2026Review
- The PhageExpressionAtlas reveals shared and unique transcriptional patterns across phage-host interactions.NAR genomics and bioinformatics · 2026Article
- Phage-encoded NARP3 system rebuilds NADScience advances · 2026Article
- CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.Cell host & microbe · 2026Article
- Review
- Inhibition by ATP regulates the activity of a CBASS anti-phage nucleotide cyclase.The Biochemical journal · 2026Article
- Phage hijacks host phosphorothioate DNA modification machinery to circumvent bacterial Ssp defences.Nature microbiology · 2026Article
- Review
- Functional diversity of phage sponge proteins that sequester host immune signals.Nature microbiology · 2026Article
- Phage RyR-domain proteins degrade ADPR-based immune signals and fuel NADbioRxiv : the preprint server for biology · 2026Article
- Genomic characterization and comparative analysis of a new Tequatrovirus phage infecting Escherichia coli ST131.BMC research notes · 2026Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
The cyclic oligonucleotide-based antiphage signalling system (CBASS) and the pyrimidine cyclase system for antiphage resistance (Pycsar) are antiphage defence systems in diverse bacteria that use cyclic nucleotide signals to induce cell death and prevent viral propagation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.